Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

EASD 2024

Keep up to date with the top stories from the 60th EASD Annual Meeting with our congress hub page.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports

03-09-2024 | Steatotic Liver Disease | REVIEW

Osteokines in Nonalcoholic Fatty Liver Disease

Authors: Ilias D. Vachliotis, Athanasios D. Anastasilakis, Vasileios Rafailidis, Stergios A. Polyzos

Published in: Current Obesity Reports

Login to get access

Abstract

Purpose of Review

To critically summarize evidence on the potential role of osteokines in the pathogenesis and progression of nonalcoholic fatty liver disease (NAFLD).

Recent Findings

There are emerging data supporting that certain osteokines, which are specific bone-derived proteins, may beneficially or adversely affect hepatic metabolism, and their alterations in the setting of osteoporosis or other bone metabolic diseases may possibly contribute to the development and progression of NAFLD. There is evidence showing a potential bidirectional association between NAFLD and bone metabolism, which may imply the existence of a liver-bone axis. In this regard, osteocalcin, osteoprotegerin, bone morphogenic protein 4 (BMP4) and BMP6 appear to have a positive impact on the liver, thus possibly alleviating NAFLD, whereas osteopontin, receptor activator of nuclear factor kappa Β ligand (RANKL), sclerostin, periostin, BMP8B, and fibroblast growth factor 23 (FGF23) appear to have a negative impact on the liver, thus possibly exacerbating NAFLD.

Summary

The potential implication of osteokines in NAFLD warrants further animal and clinical research in the field that may possibly result in novel therapeutic targets for NAFLD in the future.
Literature
1.
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82–97.PubMedCrossRef
2.
Li L, Liu D-W, Yan H-Y, Wang Z-Y, Zhao S-H, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510–9.PubMedCrossRef
3.
Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol. 2017;42:92–108.PubMedCrossRef
4.
Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52:25–37.PubMedCrossRef
5.
Polyzos SA, Mantzoros CS. Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management. Metabolism. 2024;157:155936.
6.
Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther. 2021;54:1013–25.PubMedCrossRef
7.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56.PubMedCrossRef
8.
Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46:272–84.PubMedCrossRef
9.
10.
Liang W, Wei T, Hu L, Chen M, Tong L, Zhou W, et al. An integrated multi-omics analysis reveals osteokines involved in global regulation. Cell Metab. 2024;36:1144-1163.e7.PubMedCrossRef
11.
Shimonty A, Bonewald LF, Huot JR. Metabolic health and disease: A role of osteokines? Calcif Tissue Int. 2023;113:21–38.PubMedCrossRef
12.
Vachliotis ID, Anastasilakis AD, Goulas A, Goulis DG, Polyzos SA. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes Obes Metab. 2022;24:1702–20.PubMedCrossRef
13.
Drapkina OM, Elkina AY, Sheptulina AF, Kiselev AR. Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives. Int J Mol Sci. 2023;24:8445.PubMedPubMedCentralCrossRef
14.
Azizieh FY, Shehab D, Al Jarallah K, Mojiminiyi O, Gupta R, Raghupathy R. Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD. J Inflamm Res. 2019;12:99–108.PubMedPubMedCentralCrossRef
15.
Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018;13:1879–91.PubMedPubMedCentralCrossRef
16.
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism. 2016;65:1062–79.PubMedCrossRef
17.
Shu L, Fu Y, Sun H. The association between common serum adipokines levels and postmenopausal osteoporosis: A meta-analysis. J Cell Mol Med. 2022;26:4333–42.PubMedPubMedCentralCrossRef
18.
Santos JPMD, de Maio MC, Lemes MA, Laurindo LF, Haber JFDS, Bechara MD, et al. Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. Int J Mol Sci. 2022;23:498.PubMedPubMedCentralCrossRef
19.
Ehnert S, Aspera-Werz RH, Ruoß M, Dooley S, Hengstler JG, Nadalin S, et al. Hepatic osteodystrophy-molecular mechanisms proposed to favor its development. Int J Mol Sci. 2019;20:2555.PubMedPubMedCentralCrossRef
20.
Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Yavropoulou MP, Makras P. Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations. Maturitas. 2021;147:19–25.PubMedCrossRef
21.
Zhao J, Lei H, Wang T, Xiong X. Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology. Front Endocrinol. 2023;14:1161402.CrossRef
22.
23.
Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Curr Osteoporos Rep. 2015;13:180–5.PubMedCrossRef
24.
Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009;9:299–314.PubMedCrossRef
25.
Zhang M, Nie X, Yuan Y, Wang Y, Ma X, Yin J, et al. Osteocalcin alleviates nonalcoholic fatty liver disease in mice through GPRC6A. Int J Endocrinol. 2021;2021:9178616.PubMedCentralCrossRef
26.
Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. Bone. 2012;50:568–75.PubMedCrossRef
27.
Du J, Zhang M, Lu J, Zhang X, Xiong Q, Xu Y, et al. Osteocalcin improves nonalcoholic fatty liver disease in mice through activation of Nrf2 and inhibition of JNK. Endocrine. 2016;53:701–9.PubMedCrossRef
28.
Zhang X-L, Wang Y-N, Ma L-Y, Liu Z-S, Ye F, Yang J-H. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway. Acta Pharmacol Sin. 2020;41:383–93.PubMedCrossRef
29.
Gupte AA, Sabek OM, Fraga D, Minze LJ, Nishimoto SK, Liu JZ, et al. Osteocalcin protects against nonalcoholic steatohepatitis in a mouse model of metabolic syndrome. Endocrinology. 2014;155:4697–705.PubMedPubMedCentralCrossRef
30.
Musso G, Paschetta E, Gambino R, Cassader M, Molinaro F. Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med. 2013;19:522–35.PubMedCrossRef
31.
Otani T, Mizokami A, Kawakubo-Yasukochi T, Takeuchi H, Inai T, Hirata M. The roles of osteocalcin in lipid metabolism in adipose tissue and liver. Adv Biol Regul. 2020;78: 100752.PubMedCrossRef
32.
33.
Polyzos SA, Kountouras J, Zavos C. Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatol Res. 2010;40:446–7.PubMedCrossRef
34.
Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365–83.PubMedCrossRef
35.
Dou J, Ma X, Fang Q, Hao Y, Yang R, Wang F, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. Clin Exp Pharmacol Physiol. 2013;40:282–8.PubMedCrossRef
36.
Liu J-J, Chen Y-Y, Mo Z-N, Tian G-X, Tan A-H, Gao Y, et al. Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in adult males. South China Int J Mol Sci. 2013;14:19782–91.PubMedCrossRef
37.
Luo Y-Q, Ma X-J, Hao Y-P, Pan X-P, Xu Y-T, Xiong Q, et al. Inverse relationship between serum osteocalcin levels and nonalcoholic fatty liver disease in postmenopausal Chinese women with normal blood glucose levels. Acta Pharmacol Sin. 2015;36:1497–502.PubMedPubMedCentralCrossRef
38.
Sinn DH, Gwak G-Y, Rhee SY, Cho J, Son HJ, Paik Y-H, et al. Association between serum osteocalcin levels and non-alcoholic fatty liver disease in women. Digestion. 2015;91:150–7.PubMedCrossRef
39.
Yang HJ, Shim SG, Ma BO, Kwak JY. Association of nonalcoholic fatty liver disease with bone mineral density and serum osteocalcin levels in Korean men. Eur J Gastroenterol Hepatol. 2016;28:338–44.PubMedPubMedCentralCrossRef
40.
Wang N, Wang Y, Chen X, Zhang W, Chen Y, Xia F, et al. Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes. Front Endocrinol. 2019;10:926.CrossRef
41.
Aller R, Castrillon JLP, de Luis DA, Conde R, Izaola O, Sagrado MG, et al. Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. Ann Hepatol. 2011;10:50–5.PubMedCrossRef
42.
Yilmaz Y, Kurt R, Eren F, Imeryuz N. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. Scand J Clin Lab Invest. 2011;71:631–6.PubMedCrossRef
43.
Xia M, Rong S, Zhu X, Yan H, Chang X, Sun X, et al. Osteocalcin and Non-Alcoholic Fatty Liver Disease: Lessons From Two Population-Based Cohorts and Animal Models. J Bone Miner Res. 2021;36:712–28.PubMedCrossRef
44.
Fang D, Yin H, Ji X, Sun H, Zhao X, Bi Y, et al. Low levels of osteocalcin, but not CTX or P1NP, are associated with nonalcoholic hepatic steatosis and steatohepatitis. Diabetes Metab. 2023;49: 101397.PubMedCrossRef
45.
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–9.PubMedCrossRef
46.
Wang Y-J, Jin C-H, Ke J-F, Wang J-W, Ma Y-L, Lu J-X, et al. Decreased serum osteocalcin is an independent risk factor for metabolic dysfunction-associated fatty liver disease in type 2 diabetes. Diabetes Metab Syndr Obes. 2022;15:3717–28.PubMedPubMedCentralCrossRef
47.
McKee MD, Nanci A. Osteopontin: an interfacial extracellular matrix protein in mineralized tissues. Connect Tissue Res. 1996;35:197–205.PubMedCrossRef
48.
Gimba ER, Tilli TM. Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett. 2013;331:11–7.PubMedCrossRef
49.
Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell. 2003;14:173–89.PubMedPubMedCentralCrossRef
50.
51.
Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int. 2002;71:145–54.PubMedCrossRef
52.
53.
Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302–9.PubMedCrossRef
54.
Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol. 2004;287:G264–73.PubMedCrossRef
55.
Song Z, Chen W, Athavale D, Ge X, Desert R, Das S, et al. Osteopontin takes center stage in chronic liver disease. Hepatology. 2021;73:1594–608.PubMedCrossRef
56.
Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, et al. Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia. 2011;54:2132–42.PubMedPubMedCentralCrossRef
57.
Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010;59:935–46.PubMedPubMedCentralCrossRef
58.
Honda M, Kimura C, Uede T, Kon S. Neutralizing antibody against osteopontin attenuates non-alcoholic steatohepatitis in mice. J Cell Commun Signal. 2020;14:223–32.PubMedPubMedCentralCrossRef
59.
Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, et al. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes. 2009;58:125–33.PubMedPubMedCentralCrossRef
60.
Nuñez-Garcia M, Gomez-Santos B, Buqué X, García-Rodriguez JL, Romero MR, Marin JJG, et al. Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver. J Lipid Res. 2017;58:1903–15.PubMedPubMedCentralCrossRef
61.
Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29:623–32.PubMedCrossRef
62.
Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatol Commun. 2022;6:12–35.PubMedCrossRef
63.
Tang M, Jiang Y, Jia H, Patpur BK, Yang B, Li J, et al. Osteopontin acts as a negative regulator of autophagy accelerating lipid accumulation during the development of nonalcoholic fatty liver disease. Artif Cells Nanomed Biotechnol. 2020;48:159–68.PubMedCrossRef
64.
Lancha A, Rodríguez A, Catalán V, Becerril S, Sáinz N, Ramírez B, et al. Osteopontin deletion prevents the development of obesity and hepatic steatosis via impaired adipose tissue matrix remodeling and reduced inflammation and fibrosis in adipose tissue and liver in mice. PLoS ONE. 2014;9: e98398.PubMedPubMedCentralCrossRef
65.
66.
Xu Z, Xi F, Deng X, Ni Y, Pu C, Wang D, et al. Osteopontin Promotes Macrophage M1 Polarization by Activation of the JAK1/STAT1/HMGB1 Signaling Pathway in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2023;11:273–83.PubMed
67.
Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014;3:384–93.PubMedPubMedCentralCrossRef
68.
Jiang X, Zhang F, Ji X, Dong F, Yu H, Xue M, et al. Lipid-injured hepatocytes release sOPN to improve macrophage migration via CD44 engagement and pFak-NFκB signaling. Cytokine. 2021;142: 155474.PubMedCrossRef
69.
Han H, Ge X, Komakula SSB, Desert R, Das S, Song Z, et al. Macrophage-derived Osteopontin (SPP1) Protects From Nonalcoholic Steatohepatitis. Gastroenterology. 2023;165:201–17.PubMedCrossRef
70.
Remmerie A, Martens L, Thoné T, Castoldi A, Seurinck R, Pavie B, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from kupffer cells in the fatty liver. Immunity. 2020;53:641-657.e14.PubMedPubMedCentralCrossRef
71.
Cui G, Chen J, He J, Lu C, Wei Y, Wang L, et al. Osteopontin promotes dendritic cell maturation and function in response to HBV antigens. Drug Des Devel Ther. 2015;9:3003–16.PubMedPubMedCentral
72.
Chung JW, Kim MS, Piao Z-H, Jeong M, Yoon SR, Shin N, et al. Osteopontin promotes the development of natural killer cells from hematopoietic stem cells. Stem Cells. 2008;26:2114–23.PubMedCrossRef
73.
74.
Soysouvanh F, Rousseau D, Bonnafous S, Bourinet M, Strazzulla A, Patouraux S, et al. Osteopontin-driven T-cell accumulation and function in adipose tissue and liver promoted insulin resistance and MAFLD. Obesity. 2023;31:2568–82.PubMedCrossRef
75.
Bruha R, Vitek L, Smid V. Osteopontin - A potential biomarker of advanced liver disease. Ann Hepatol. 2020;19:344–52.PubMedCrossRef
76.
77.
Syn W-K, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology. 2011;53:106–15.PubMedCrossRef
78.
Syn W-K, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, et al. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut. 2012;61:1323–9.PubMedCrossRef
79.
Urtasun R, Lopategi A, George J, Leung T-M, Lu Y, Wang X, et al. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology. 2012;55:594–608.PubMedCrossRef
80.
Lorena D, Darby IA, Gadeau A-P, Leen LLS, Rittling S, Porto LC, et al. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol. 2006;44:383–90.PubMedCrossRef
81.
Arriazu E, Ge X, Leung T-M, Magdaleno F, Lopategi A, Lu Y, et al. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut. 2017;66:1123–37.PubMedCrossRef
82.
Xiao X, Gang Y, Gu Y, Zhao L, Chu J, Zhou J, et al. Osteopontin contributes to TGF-β1 mediated hepatic stellate cell activation. Dig Dis Sci. 2012;57:2883–91.PubMedCrossRef
83.
Coombes JD, Choi SS, Swiderska-Syn M, Manka P, Reid DT, Palma E, et al. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. Biochim Biophys Acta. 2016;1862:135–44.PubMedCrossRef
84.
Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn W-K, et al. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2:1344–55.PubMedPubMedCentralCrossRef
85.
Kriss M, Golden-Mason L, Kaplan J, Mirshahi F, Setiawan VW, Sanyal AJ, et al. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS ONE. 2020;15: e0236353.PubMedPubMedCentralCrossRef
86.
Yilmaz Y, Ozturk O, Alahdab YO, Senates E, Colak Y, Doganay HL, et al. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. Dig Liver Dis. 2013;45:58–62.PubMedCrossRef
87.
Wang C, He M, Peng J, Li S, Long M, Chen W, et al. Increased plasma osteopontin levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Cytokine. 2020;125: 154837.PubMedCrossRef
88.
Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179:R31-45.PubMedCrossRef
89.
Gkastaris K, Goulis DG, Potoupnis M, Anastasilakis AD, Kapetanos G. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact. 2020;20:372–81.PubMedPubMedCentral
90.
Tsukasaki M, Asano T, Muro R, Huynh NC-N, Komatsu N, Okamoto K, et al. OPG Production Matters Where It Happened. Cell Rep. 2020;32:108124.PubMedCrossRef
91.
Polyzos SA, Makras P, Tournis S, Anastasilakis AD. Off-label uses of denosumab in metabolic bone diseases. Bone. 2019;129: 115048.PubMedCrossRef
92.
Vachliotis ID, Polyzos SA. Osteoprotegerin/receptor activator of nuclear factor-kappa B ligand/receptor activator of nuclear factor-kappa B axis in obesity, type 2 diabetes mellitus, and nonalcoholic fatty liver disease. Curr Obes Rep. 2023;12:147–62.PubMedPubMedCentralCrossRef
93.
Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, et al. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol. 2014;394:13–20.PubMedCrossRef
94.
Karmakar S, Majumdar S, Maiti A, Choudhury M, Ghosh A, Das AS, et al. Protective role of black tea extract against nonalcoholic steatohepatitis-induced skeletal dysfunction. J Osteoporos. 2011;2011:426863.PubMedPubMedCentralCrossRef
95.
Zhong L, Yuan J, Huang L, Li S, Deng L. RANKL is involved in Runx2-triggered hepatic infiltration of macrophages in mice with NAFLD induced by a high-fat diet. Biomed Res Int. 2020;2020:6953421.PubMedPubMedCentralCrossRef
96.
Kiechl S, Wittmann J, Giaccari A, Knoflach M, Willeit P, Bozec A, et al. Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013;19:358–63.PubMedCrossRef
97.
Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han C-Y, et al. Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice. J Bone Miner Res. 2014;29:1158–69.PubMedCrossRef
98.
Polyzos SA, Goulas A. Treatment of nonalcoholic fatty liver disease with an anti-osteoporotic medication: A hypothesis on drug repurposing. Med Hypotheses. 2021;146: 110379.PubMedCrossRef
99.
Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, et al. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS ONE. 2015;10: e0131664.PubMedPubMedCentralCrossRef
100.
Yang M, Liu Y, Zhou G, Guo X, Zou S, Liu S, et al. Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2016;24:96–101.PubMed
101.
Habibie H, Adhyatmika A, Schaafsma D, Melgert BN. The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases. Pharmacol Ther. 2021;228: 107941.PubMedCrossRef
102.
Mantovani A, Sani E, Fassio A, Colecchia A, Viapiana O, Gatti D, et al. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. Diabetes Metab. 2019;45:347–55.PubMedCrossRef
103.
Nikseresht M, Azarmehr N, Arya A, Alipoor B, Fadaei R, Khalvati B, et al. Circulating mRNA and plasma levels of osteoprotegerin and receptor activator of NF-κB ligand in nonalcoholic fatty liver disease. Biotechnol Appl Biochem. 2021;68:1243–9.PubMed
104.
Takeno A, Yamamoto M, Notsu M, Sugimoto T. Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report. BMC Endocr Disord. 2016;16:66.PubMedPubMedCentralCrossRef
105.
106.
Lu Y, Liu X, Jiao Y, Xiong X, Wang E, Wang X, et al. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα. J Clin Invest. 2014;124:3501–13.PubMedPubMedCentralCrossRef
107.
Jia Y, Zhong F, Jiang S, Guo Q, Jin H, Wang F, et al. Periostin in chronic liver diseases: Current research and future perspectives. Life Sci. 2019;226:91–7.PubMedCrossRef
108.
Polyzos SA, Anastasilakis AD. Periostin on the road to nonalcoholic fatty liver disease. Endocrine. 2016;51:4–6.PubMedCrossRef
109.
Zhu J-Z, Zhu H-T, Dai Y-N, Li C-X, Fang Z-Y, Zhao D-J, et al. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine. 2016;51:91–100.PubMedCrossRef
110.
Yang Z, Zhang H, Niu Y, Zhang W, Zhu L, Li X, et al. Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects. Sci Rep. 2016;6:37886.PubMedPubMedCentralCrossRef
111.
Polyzos SA, Kountouras J, Anastasilakis AD, Papatheodorou A, Kokkoris P, Terpos E. Circulating periostin in patients with nonalcoholic fatty liver disease. Endocrine. 2017;56:438–41.PubMedCrossRef
112.
Smirne C, Mulas V, Barbaglia MN, Mallela VR, Minisini R, Barizzone N, et al. Periostin circulating levels and genetic variants in patients with non-alcoholic fatty liver disease. Diagnostics (Basel). 2020;10:1003.PubMedCrossRef
113.
Anastasilakis AD, Polyzos SA, Toulis KA. Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge. Curr Opin Endocrinol Diabetes Obes. 2011;18:383–8.PubMedCrossRef
114.
Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the osteocyte. Bone. 2017;96:45–50.PubMedCrossRef
115.
Magarò MS, Bertacchini J, Florio F, Zavatti M, Potì F, Cavani F, et al. Identification of sclerostin as a putative new myokine involved in the muscle-to-bone crosstalk. Biomedicines. 2021;9:71.PubMedPubMedCentralCrossRef
116.
Oh H, Park SY, Cho W, Abd El-Aty AM, Hacimuftuoglu A, Kwon CH, et al. Sclerostin aggravates insulin signaling in skeletal muscle and hepatic steatosis via upregulation of ER stress by mTOR-mediated inhibition of autophagy under hyperlipidemic conditions. J Cell Physiol. 2022;237:4226–37.PubMedCrossRef
117.
Zhou F, Wang Y, Li Y, Tang M, Wan S, Tian H, et al. Decreased sclerostin secretion in humans and mice with nonalcoholic fatty liver disease. Front Endocrinol. 2021;12: 707505.CrossRef
118.
Polyzos SA, Anastasilakis AD, Kountouras J, Makras P, Papatheodorou A, Kokkoris P, et al. Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J Bone Miner Metab. 2016;34:447–56.PubMedCrossRef
119.
Li Z, Wen X, Li N, Zhong C, Chen L, Zhang F, et al. The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects. Front Endocrinol (Lausanne). 2023;14:1149233.PubMedCrossRef
120.
Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, et al. TGF-β signalling and liver disease. FEBS J. 2016;283:2219–32.PubMedCrossRef
121.
Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72.PubMedPubMedCentralCrossRef
122.
Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol. 2022;13: 880298.PubMedPubMedCentralCrossRef
123.
Herrera B, Addante A, Sánchez A. BMP signalling at the crossroad of liver fibrosis and regeneration. Int J Mol Sci. 2017;19:1.CrossRef
124.
Peng Q, Chen B, Wang H, Zhu Y, Wu J, Luo Y, et al. Bone morphogenetic protein 4 (BMP4) alleviates hepatic steatosis by increasing hepatic lipid turnover and inhibiting the mTORC1 signaling axis in hepatocytes. Aging. 2019;11:11520–40.PubMedPubMedCentralCrossRef
125.
Wang X, Ma B, Wen X, You H, Sheng C, Bu L, et al. Bone morphogenetic protein 4 alleviates nonalcoholic steatohepatitis by inhibiting hepatic ferroptosis. Cell Death Discov. 2022;8:234.PubMedPubMedCentralCrossRef
126.
Arndt S, Wacker E, Dorn C, Koch A, Saugspier M, Thasler WE, et al. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease. Gut. 2015;64:973–81.PubMedCrossRef
127.
Mahli A, Seitz T, Beckröge T, Freese K, Thasler WE, Benkert M, et al. Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. Cells. 2019;8:457.PubMedPubMedCentralCrossRef
128.
Vacca M, Leslie J, Virtue S, Lam BYH, Govaere O, Tiniakos D, et al. Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. Nat Metab. 2020;2:514–31.PubMedCrossRef
129.
Mounika N, Yadav A, Kamboj P, Banerjee SK, Deka UJ, Kaur S, et al. Circulatory bone morphogenetic protein (BMP) 8B is a non-invasive predictive biomarker for the diagnosis of non-alcoholic steatohepatitis (NASH). PLoS ONE. 2023;18: e0295839.PubMedPubMedCentralCrossRef
130.
Marañón P, Isaza SC, Fernández-García CE, Rey E, Gallego-Durán R, Montero-Vallejo R, et al. Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis. Biomark Res. 2023;11:46.PubMedPubMedCentralCrossRef
131.
Jiang Q-Q, Liu B-B, Xu K-S. New insights into BMP9 signaling in liver diseases. Mol Cell Biochem. 2021;476:3591–600.PubMedCrossRef
132.
Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90:985–96.PubMedPubMedCentralCrossRef
133.
Mattinzoli D, Ikehata M, Tsugawa K, Alfieri CM, Dongiovanni P, Trombetta E, et al. FGF23 and fetuin-A interaction in the liver and in the circulation. Int J Biol Sci. 2018;14:586–98.PubMedPubMedCentralCrossRef
134.
He X, Shen Y, Ma X, Ying L, Peng J, Pan X, et al. The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol. 2018;45:668–74.PubMedCrossRef
135.
Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y. Serum fibroblast growth factor 23 level and liver fat content in MAFLD: A community-based cohort. Diabetes Metab Syndr Obes. 2021;14:4135–43.PubMedPubMedCentralCrossRef
136.
Kord-Varkaneh H, Djafarian K, Khorshidi M, Shab-Bidar S. Association between serum osteocalcin and body mass index: a systematic review and meta-analysis. Endocrine. 2017;58:24–32.PubMedCrossRef
137.
Kiefer FW, Zeyda M, Todoric J, Huber J, Geyeregger R, Weichhart T, et al. Osteopontin expression in human and murine obesity: extensive local up-regulation in adipose tissue but minimal systemic alterations. Endocrinology. 2008;149:1350–7.PubMedCrossRef
138.
Chen J, Zeng P, Gong L, Zhang X, Ling Z, Bi K, et al. Osteopontin exacerbates high-fat diet-induced metabolic disorders in a microbiome-dependent manner. MBio. 2022;13: e0253122.PubMedCrossRef
139.
Vianello E, Kalousová M, Dozio E, Tacchini L, Zima T, Corsi Romanelli MM. Osteopontin: The molecular bridge between fat and cardiac-renal disorders. Int J Mol Sci. 2020;21:5568.PubMedPubMedCentralCrossRef
140.
Gómez-Ambrosi J, Catalán V, Ramírez B, Rodríguez A, Colina I, Silva C, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007;92:3719–27.PubMedCrossRef
141.
Ahmad R, Al-Mass A, Al-Ghawas D, Shareif N, Zghoul N, Melhem M, et al. Interaction of osteopontin with IL-18 in obese individuals: implications for insulin resistance. PLoS ONE. 2013;8: e63944.PubMedPubMedCentralCrossRef
142.
You JS, Ji H-I, Chang KJ, Yoo MC, Yang H-I, Jeong I-K, et al. Serum osteopontin concentration is decreased by exercise-induced fat loss but is not correlated with body fat percentage in obese humans. Mol Med Rep. 2013;8:579–84.PubMedCrossRef
143.
Schaller G, Aso Y, Schernthaner G-H, Kopp H-P, Inukai T, Kriwanek S, et al. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg. 2009;19:351–6.PubMedCrossRef
144.
Riedl M, Vila G, Maier C, Handisurya A, Shakeri-Manesch S, Prager G, et al. Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab. 2008;93:2307–12.PubMedCrossRef
145.
Nakazeki F, Nishiga M, Horie T, Nishi H, Nakashima Y, Baba O, et al. Loss of periostin ameliorates adipose tissue inflammation and fibrosis in vivo. Sci Rep. 2018;8:8553.PubMedPubMedCentralCrossRef
146.
Yang Y, Zhang Y, Zhou X, Chen D, Ouyang G, Liu Y, et al. Periostin deficiency attenuates lipopolysaccharide- and obesity-induced adipose tissue fibrosis. FEBS Lett. 2021;595:2099–112.PubMedCrossRef
147.
Luo Y, Qu H, Wang H, Wei H, Wu J, Duan Y, et al. Plasma periostin levels are increased in Chinese subjects with obesity and type 2 diabetes and are positively correlated with glucose and lipid parameters. Mediators Inflamm. 2016;2016:6423637.PubMedPubMedCentralCrossRef
148.
Dimitri P, Wales JK, Bishop N. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone. 2011;48:189–96.PubMedCrossRef
149.
Ashley DT, O’Sullivan EP, Davenport C, Devlin N, Crowley RK, McCaffrey N, et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. Metabolism. 2011;60:994–1000.PubMedCrossRef
150.
Courtalin M, Bertheaume N, Badr S, During A, Lombardo D, Deken V, et al. Relationships between circulating sclerostin, bone marrow adiposity, other adipose deposits and lean mass in post-menopausal women. Int J Mol Sci. 2023;24:5922.PubMedPubMedCentralCrossRef
151.
Alramah T, Cherian P, Al-Khairi I, Abu-Farha M, Thanaraj TA, Albatineh AN, et al. Evaluating the correlation of sclerostin levels with obesity and type 2 diabetes in a multiethnic population living in Kuwait. Front Endocrinol (Lausanne). 2024;15:1392675.PubMedPubMedCentralCrossRef
152.
Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS ONE. 2015;10: e0122885.PubMedPubMedCentralCrossRef
153.
Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, et al. Associations of serum fibroblast growth factor 23 levels with obesity and visceral fat accumulation. Clin Nutr. 2018;37:223–8.PubMedCrossRef
154.
Holecki M, Chudek J, Owczarek A, Olszanecka-Glinianowicz M, Bożentowicz-Wikarek M, Duława J, et al. Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly. Clin Endocrinol. 2015;82:900–9.CrossRef
155.
Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos SA, Deng Y, Kokkorakis M, et al. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study. Metabolism. 2023;147: 155666.PubMedCrossRef
Metadata
Title
Osteokines in Nonalcoholic Fatty Liver Disease
Authors
Ilias D. Vachliotis
Athanasios D. Anastasilakis
Vasileios Rafailidis
Stergios A. Polyzos
Publication date
03-09-2024
Publisher
Springer US
Published in
Current Obesity Reports
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-024-00586-9

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits